scPharmaceuticals Inc., a clinical-stage pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix, a drug-device combination product that is under development for treatment of worsening or decompensated heart failure outside of the inpatient setting. Its product pipeline also includes scFurosemide, a loop diuretic for the management of edema in patients with decompensated heart failure; scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company was founded in 2013 and is headquartered in Burlington, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SCPH
CUSIPN/A
Phone617-517-0730
Debt
Debt-to-Equity Ratio0.10
Current Ratio19.23
Quick Ratio19.23
Price-To-Earnings
Trailing P/E Ratio-0.67
Forward P/E Ratio-2.42
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$6.02 per share
Price / Book0.89
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees29
Outstanding Shares18,570,000
Market Cap$85.11 million
Scpharmaceuticals (NASDAQ:SCPH) Frequently Asked Questions
What is Scpharmaceuticals' stock symbol?
Scpharmaceuticals trades on the NASDAQ under the ticker symbol "SCPH."
How were Scpharmaceuticals' earnings last quarter?
Scpharmaceuticals Inc (NASDAQ:SCPH) issued its quarterly earnings data on Tuesday, August, 14th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.57) by $0.04. View Scpharmaceuticals' Earnings History.
When is Scpharmaceuticals' next earnings date?
What price target have analysts set for SCPH?
3 Wall Street analysts have issued 1 year price objectives for Scpharmaceuticals' shares. Their predictions range from $12.00 to $14.00. On average, they expect Scpharmaceuticals' stock price to reach $12.6667 in the next year. This suggests a possible upside of 135.9% from the stock's current price. View Analyst Price Targets for Scpharmaceuticals.
What is the consensus analysts' recommendation for Scpharmaceuticals?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Scpharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Scpharmaceuticals.
Who are some of Scpharmaceuticals' key competitors?
Some companies that are related to Scpharmaceuticals include Minerva Neurosciences (NERV), Seres Therapeutics (MCRB), Innate Pharma (IPHYF), Avid Bioservices (CDMO), Kezar Life Sciences (KZR), resTORbio (TORC), Paratek Pharmaceuticals (PRTK), Corium International (CORI), Sienna Biopharmaceuticals (SNNA), Kala Pharmaceuticals (KALA), Selecta Biosciences (SELB), Catalyst Pharmaceuticals (CPRX), Mersana Therapeutics (MRSN), CELYAD SA/ADR (CYAD) and BIOFRONTERA AG/ADR (BFRA).
Who are Scpharmaceuticals' key executives?
Scpharmaceuticals' management team includes the folowing people:
- Mr. John H. Tucker, Pres, CEO & Director (Age 55)
- Dr. Troy A. Ignelzi, Chief Financial Officer (Age 50)
- Mr. Abraham Ceesay, Chief Operating Officer (Age 40)
- Dr. Pieter Muntendam M.D., Consultant (Age 60)
- Katherine Taudvin, Director of Corp. Devel. & Investor Relations
When did Scpharmaceuticals IPO?
(SCPH) raised $96 million in an IPO on Friday, November 17th 2017. The company issued 6,400,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.
Has Scpharmaceuticals been receiving favorable news coverage?
Media coverage about SCPH stock has trended somewhat positive recently, Accern Sentiment reports. The research group ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Scpharmaceuticals earned a news and rumor sentiment score of 0.17 on Accern's scale. They also assigned press coverage about the company an impact score of 48.57 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future. View Recent Headlines for Scpharmaceuticals.
Who are Scpharmaceuticals' major shareholders?
Which institutional investors are buying Scpharmaceuticals stock?
How do I buy shares of Scpharmaceuticals?
Shares of SCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Scpharmaceuticals' stock price today?
One share of SCPH stock can currently be purchased for approximately $5.37.
How big of a company is Scpharmaceuticals?
Scpharmaceuticals has a market capitalization of $85.11 million. The company earns $-23,810,000.00 in net income (profit) each year or ($8.04) on an earnings per share basis. Scpharmaceuticals employs 29 workers across the globe.
How can I contact Scpharmaceuticals?
Scpharmaceuticals' mailing address is 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA, 01830. The company can be reached via phone at 617-517-0730 or via email at [email protected]
MarketBeat Community Rating for Scpharmaceuticals (NASDAQ SCPH)
MarketBeat's community ratings are surveys of what our community members think about Scpharmaceuticals and other stocks. Vote "Outperform" if you believe SCPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SCPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
